Ionis Pharmaceuticals Inc (IONS) Gets a Hold Rating from Cowen & Co.

In a report released today, Ritu Baral from Cowen & Co. maintained a Hold rating on Ionis Pharmaceuticals Inc (IONSResearch Report). The company’s shares closed last Monday at $54.73.

According to TipRanks.com, Baral is a 5-star analyst with an average return of 20.1% and a 43.9% success rate. Baral covers the Healthcare sector, focusing on stocks such as Milestone Pharmaceuticals Inc, Madrigal Pharmaceuticals Inc, and ACADIA Pharmaceuticals Inc.

Currently, the analyst consensus on Ionis Pharmaceuticals Inc is a Moderate Buy with an average price target of $77.29, a 39.5% upside from current levels. In a report issued on October 15, Cantor Fitzgerald also maintained a Hold rating on the stock with a $65.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $86.58 and a one-year low of $48.27. Currently, Ionis Pharmaceuticals Inc has an average volume of 1.03M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs.